Pfizer And Valneva Announce Primary Vaccination Series Completion In Phase 3 VALOR Lyme Disease Trial; Participants Completed Primary Vaccination Series (3 Doses) With VLA15

• Participants completed primary vaccination series (3 doses) with VLA15
  
   
• Primary vaccination series to be followed by a booster approximately one year after completion

New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the participants of the Phase 3 trial "Vaccine Against Lyme for Outdoor Recreationists" (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.1,